Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15898945 | 0.81 | EPHX2 (0.45) | MAPTPOLBLMNA | |
| SCHEMBL26525546 | 0.75 | MAPT (0.64) | MAPTTP53POLBLMNAHTR2C | |
| SCHEMBL9689456 | 0.73 | MAPT (0.62) | MAPTTP53POLBLMNAHTR2C | |
| SCHEMBL17321017 | 0.72 | THRB (0.46) | MAPTTP53POLBTHRB | |
| SCHEMBL5985206 | 0.67 | MAPT (0.53) | MAPTTP53LMNAHTR2CTHRB | |
| SCHEMBL3119452 | 0.67 | LMNA (0.55) | MAPTTP53LMNA | |
| SCHEMBL17321018 | 0.67 | MAPT (0.55) | MAPTPOLBTDP1 | |
| SCHEMBL2535956 | 0.66 | MEN1 (0.47) | MAPTTP53POLBTDP1 | |
| SCHEMBL6785437 | 0.65 | CA1 (0.44) | LMNAHTR2C | |
| SCHEMBL5643020 | 0.65 | TAAR1 (0.44) | POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MAPT 828/4885TP53 2461/4885POLB 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.